Study Links Common Ovarian Disorder to Higher Alzheimer Risk, Calls for More Research
Researchers say polyendocrine metabolic ovarian syndrome may raise Alzheimer’s risk, but evidence is mixed and focus should stay on metabolic health.
A new review published in the Journal of the Endocrine Society examined data through October 2025 on polyendocrine metabolic ovarian syndrome (PMOS) and its possible connection to Alzheimer’s disease. The authors highlighted a Canadian cohort of over 16,000 women with PMOS that reported higher dementia rates and younger onset, contrasted with a UK Biobank study of about 1,000 PMOS patients that found no significant association after controlling for body-mass index and insulin resistance.
The inconsistency appears tied to study design and how well metabolic variables are accounted for, with stronger links observed in women with obesity or insulin resistance. Researchers argue that metabolic and vascular comorbidities, rather than PMOS itself, likely underlie any cognitive risk, though hormonal mechanisms remain speculative. They advise clinicians to concentrate on optimizing metabolic health through diet, exercise, and insulin-sensitizing treatments, and call for large, long-term studies to determine whether PMOS independently raises dementia risk.
Why it matters
Clarifying any link between a widespread women's condition and dementia could shape prevention and treatment approaches.
In this story
